Moderna wins patent lawsuit against BioNTech/Pfizer
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...
Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...
Moderna, Inc. ( NASDAQ: MRNA) TD Cowen 45th Annual Health Care Conference March 5, 2025 9:10 AM ET All right, well, good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen.
For now, Moderna may be a good stock to put on a watch list, but it's likely too risky and volatile for the vast majority of ...
The Trump administration confirmed it is reevaluating a $590 million human bird flu vaccine contract awarded to Moderna in ...
The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that ...
Moderna, Inc. (Nasdaq: MRNA), today announced its participation in the following upcoming investor conferences: ...
(Bloomberg) -- US health officials are reevaluating a $590 million contract for bird flu shots that the Biden administration awarded to Moderna Inc., people familiar with the matter said.
Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback